Chrisann Kyi
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chrisann Kyi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:07 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04106414 · Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to TreatmentMemorial Sloan Kettering Cancer Center · active not recruiting · Endometrial Adenocarcinoma, Endometrial Carcinosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:07 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.J Immunother Cancer · 2021190 citationsRCR 9.3
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.J Immunother Cancer · 2022158 citationsRCR 9.8
- 135 citationsRCR 13.6
- A controlled clinical trial of the effects of the Twin Block and Dynamax appliances on the hard and soft tissues.Eur J Orthod · 200740 citationsRCR 2.1
- Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.J Immunother Cancer · 201738 citationsRCR 1.0
- A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.Oncoimmunology · 202334 citationsRCR 2.4
- Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.Nat Med · 202427 citationsRCR 2.4
- Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.Gynecol Oncol · 202318 citationsRCR 1.3
- A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).Gynecol Oncol · 202413 citationsRCR 1.5
- A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.Gynecol Oncol · 202111 citationsRCR 0.5